Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 28541469.
- Also identified by DOI 10.1093/cid/cix477 and PMC identifier 6248624.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Babesiosis treatment failures with standard therapy have been reported, but the molecular mechanisms are not well understood. We describe the emergence of atovaquone and azithromycin resistance associated with mutations in the binding regions of the target proteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.
Medical subject headings
- Antiprotozoal Agents
- Atovaquone
- Azithromycin
- Babesiosis
- Drug Resistance
- Leukemia, Lymphocytic, Chronic, B-Cell
- Rituximab